Cellectis S.A.(CLLS)Earnings, Financials & Key Ratios
CLLS•NASDAQ
Price updated Jun 19, 2026
AboutCellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma; ALLO-316 for the treatment of Renal Cell Carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART22 to treat B-cell acute lymphoblastic leukemia. It is also developing UCARTCS1 and ALLO-715 for the treatment of multiple myeloma. The company has strategic alliances with Allogene Therapeutics, Inc.; Les Laboratoires Servier; The University of Texas M.D. Anderson Cancer Center; and Iovance Biotherapeutics, as well as a strategic research and development collaboration with Cytovia Therapeutics, Inc. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.Show more
- Revenue$73M+75.8%
- EBITDA-$13M+67.2%
- Net Income-$68M-83.9%
- EPS (Diluted)-0.68-65.9%
- Gross Margin86.57%+11.2%
- EBITDA Margin-17.84%+81.4%
- Operating Margin-45.34%+68.4%
- Net Margin-92.66%-4.6%
- ROE-65.33%-91.7%
CLLS Key Insights
Cellectis S.A. (CLLS) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
No significant strengths identified
✗Weaknesses
- ✗Weak Piotroski F-Score: 3/9
- ✗Negative free cash flow
- ✗Weak momentum: RS Rating 15 (bottom 15%)
- ✗Shares diluted 10.7% in last year
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when CLLS posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
CLLS Price & Volume
Cellectis S.A. (CLLS) stock price & volume — 10-year historical chart
Loading chart...
CLLS Growth Metrics
Cellectis S.A. (CLLS) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years2.86%
5 Years7.4%
3 Years56.12%
TTM42.95%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-11.17%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-8.45%
Return on Capital
10 Years-28.26%
5 Years-31.94%
3 Years-32.77%
Last Year-16.69%
CLLS Recent Earnings
Cellectis S.A. (CLLS) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 6/12 qtrs (50%)●Beat Revenue 5/12 qtrs (42%)
Q2 2026Latest
May 11, 2026Metric
Actual
Est
EPS
$0.18+30.3%
$0.26
Rev
$8M-31.6%
$11M
Q2 2026
Mar 19, 2026Metric
Actual
Est
EPS
$0.26-27.9%
$0.20
Rev
$12M-8.9%
$13M
Q4 2025
Nov 7, 2025Metric
Actual
Est
EPS
$0.01+110.0%
$0.10
Rev
$35M+242.4%
$10M
Q3 2025
Aug 4, 2025Metric
Actual
Est
EPS
$0.24-140.0%
$0.10
Rev
$17M+106.0%
$8M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 11, 2026 | $0.18vs $0.26+30.3% | $8Mvs $11M-31.6% |
| Q2 2026 | Mar 19, 2026 | $0.26vs $0.20-27.9% | $12Mvs $13M-8.9% |
| Q4 2025 | Nov 7, 2025 | $0.01vs $0.10+110.0% | $35Mvs $10M+242.4% |
| Q3 2025 | Aug 4, 2025 | $0.24vs $0.10-140.0% | $17Mvs $8M+106.0% |
Based on last 12 quarters of dataView full earnings history →
CLLS Peer Comparison
Cellectis S.A. (CLLS) competitors in Cell and Gene Therapy Developers — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 CRSP | 5.22B | 54.09 | -8.36 | -89.97% | -138.57% | -30.88% | 0.21 | |
 BEAM | 3.51B | 34.14 | -42.15 | 120.01% | -49.17% | -5.89% | 0.24 | |
 EDIT | 263.37M | 2.69 | -1.49 | 25.39% | -281.59% | -6.77% | 2.81 | |
 NTLA | 1.76B | 15.67 | -4.11 | 16.92% | -5.97% | -57.27% | 0.14 | |
 FATE | 243.61M | 2.09 | -1.82 | -51.24% | -20.57% | -58.89% | 0.38 | |
 ALLO | 487.74M | 2.00 | -2.30 | -100% | -56.45% | 0.26 | ||
 SANA | 876.62M | 3.15 | -3.28 | -161.87% | 0.49 | |||
 CABA | 463.08M | 2.84 | -1.73 | -131.58% | 0.24 |
Compare CLLS vs Peers
Cellectis S.A. (CLLS) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
CLLS Income Statement
Cellectis S.A. (CLLS) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 25.19M | 12.73M | 15.19M | 51.06M | 30.35M | 19.17M | 755K | 41.51M | 72.95M | 68.09M |
Revenue Growth % | -40.85% | -49.46% | 19.32% | 236.12% | -40.56% | -36.83% | -96.06% | 5397.48% | 75.76% | 42.95% |
Cost of Goods Sold | 2.62M | 2.74M | 11.39M | 1.95M | 1.84M | 8.48M | 7.42M | 9.18M | 9.8M | 12.33M |
COGS % of Revenue | 10.4% | 21.51% | 75% | 3.82% | 6.08% | 44.25% | 982.65% | 22.12% | 13.43% | - |
Gross Profit | 22.57M▲ 0% | 9.99M▼ 55.7% | 3.8M▼ 62.0% | 49.11M▲ 1192.9% | 28.5M▼ 42.0% | 10.69M▼ 62.5% | -6.66M▼ 162.4% | 32.32M▲ 585.1% | 63.15M▲ 95.4% | 55.76M▲ 0% |
Gross Margin % | 89.6% | 78.49% | 25% | 96.18% | 93.92% | 55.75% | -882.65% | 77.88% | 86.57% | 81.89% |
Gross Profit Growth % | -44.82% | -55.72% | -61.99% | 1192.94% | -41.96% | -62.5% | -162.36% | 585.05% | 95.37% | - |
Operating Expenses | 115.22M | 115.08M | 127.35M | 91.42M | 131.98M | 100.35M | 90.64M | 91.88M | 96.23M | 101.75M |
OpEx % of Revenue | 457.43% | 903.96% | 838.38% | 179.05% | 434.93% | 523.46% | 12005.03% | 221.36% | 131.91% | - |
Selling, General & Admin | 44.75M | 47.25M | 43.02M | 22.51M | 22.88M | 8.89M | 8.12M | 8.42M | 8.6M | 9.18M |
SG&A % of Revenue | 177.66% | 371.13% | 283.19% | 44.1% | 75.4% | 46.4% | 1075.36% | 20.29% | 11.78% | - |
Research & Development | 79.23M | 76.57M | 92.04M | 77.05M | 117.84M | 97.5M | 87.65M | 90.54M | 93.52M | 94.68M |
R&D % of Revenue | 314.54% | 601.42% | 605.94% | 150.91% | 388.32% | 508.59% | 11608.74% | 218.13% | 128.19% | - |
Other Operating Expenses | -17.9M | -25.42M | -7.71M | -8.14M | -8.74M | -6.04M | -5.13M | -7.08M | -5.88M | -2M |
Operating Income | -92.65M▲ 0% | -105.09M▼ 13.4% | -123.55M▼ 17.6% | -42.31M▲ 65.8% | -103.48M▼ 144.6% | -89.67M▲ 13.4% | -97.3M▼ 8.5% | -59.55M▲ 38.8% | -33.08M▲ 44.5% | -46M▲ 0% |
Operating Margin % | -367.83% | -825.47% | -813.38% | -82.87% | -341% | -467.72% | -12887.68% | -143.48% | -45.34% | -67.55% |
Operating Income Growth % | -44.85% | -13.43% | -17.57% | 65.75% | -144.57% | 13.35% | -8.52% | 38.79% | 44.46% | - |
EBITDA | -89.28M | -102.71M | -116.68M | -34.48M | -89.33M | -71.23M | -78.78M | -39.71M | -13.01M | -26.31M |
EBITDA Margin % | -354.45% | -806.8% | -768.12% | -67.53% | -294.36% | -371.56% | -10434.3% | -95.67% | -17.84% | -38.64% |
EBITDA Growth % | -44.58% | -15.05% | -13.59% | 70.45% | -159.09% | 20.26% | -10.6% | 49.6% | 67.23% | 19.36% |
D&A (Non-Cash Add-back) | 3.37M | 2.38M | 6.88M | 7.83M | 14.16M | 18.43M | 18.52M | 19.85M | 20.06M | 19.68M |
EBIT | -103.68M | -88.29M | -112.61M | -51.17M | -92.58M | -94.81M | -111.16M | -29.31M | -59.91M | -70.79M |
Net Interest Income | 1.41M | 6.06M | 4.02M | -1.69M | -3.65M | -2.67M | -1.69M | 3.83M | 1.39M | -25.76K |
Interest Income | 1.97M | 6.79M | 6.98M | 1.96M | 719K | 1.12M | 3.61M | 11.28M | 9.5M | 8.47M |
Interest Expense | 560K | 723K | 2.96M | 3.65M | 4.37M | 3.79M | 5.31M | 7.45M | 8.11M | 8.49M |
Other Income/Expense | -11.03M | 16.76M | 8.34M | -11.27M | 6.73M | -8.94M | -19.16M | 22.79M | -34.94M | -23.45M |
Pretax Income | -103.68M▲ 0% | -88.33M▲ 14.8% | -115.21M▼ 30.4% | -53.58M▲ 53.5% | -96.75M▼ 80.6% | -98.6M▼ 1.9% | -116.46M▼ 18.1% | -36.76M▲ 68.4% | -68.02M▼ 85.0% | -69.45M▲ 0% |
Pretax Margin % | -411.63% | -693.84% | -758.47% | -104.94% | -318.83% | -514.32% | -15425.7% | -88.57% | -93.24% | -102% |
Income Tax | -13.2M | 0 | 0 | 0 | -3K | 87K | 371K | 0 | -423K | -2.16M |
Effective Tax Rate % | 12.73% | 0% | 0% | 0% | 0% | -0.09% | -0.32% | 0% | 0.62% | 3.1% |
Net Income | -99.37M▲ 0% | -78.69M▲ 20.8% | -102.09M▼ 29.7% | -81.07M▲ 20.6% | -114.2M▼ 40.9% | -106.14M▲ 7.1% | -101.06M▲ 4.8% | -36.76M▲ 63.6% | -67.59M▼ 83.9% | -67.29M▲ 0% |
Net Margin % | -394.51% | -618.12% | -672.09% | -158.79% | -376.32% | -553.64% | -13385.3% | -88.57% | -92.66% | -98.83% |
Net Income Growth % | -55.46% | 20.81% | -29.73% | 20.59% | -40.86% | 7.06% | 4.79% | 63.62% | -83.87% | -11.17% |
Net Income (Continuing) | -103.68M | -88.33M | -115.21M | -53.58M | -96.75M | -98.69M | -116.83M | -36.76M | -67.59M | -67.29M |
Discontinued Operations | 0 | 0 | 0 | -43.9M | -28.36M | -15.35M | 8.39M | 0 | 0 | 0 |
Minority Interest | 19.11M | 40.97M | 40.35M | 25.05M | 15.18M | 7.97M | 0 | 0 | 0 | 0 |
EPS (Diluted) | -2.78▲ 0% | -1.93▲ 30.6% | -2.14▼ 10.9% | -1.71▲ 20.1% | -1.93▼ 12.9% | -2.33▼ 20.7% | -1.77▲ 24.0% | -0.41▲ 76.8% | -0.68▼ 65.9% | -0.67▲ 0% |
EPS Growth % | -56.18% | 30.58% | -10.88% | 20.09% | -12.87% | -20.73% | 24.03% | 76.84% | -65.85% | -8.45% |
EPS (Basic) | -2.78 | -1.93 | -2.14 | -1.71 | -1.93 | -2.33 | -1.77 | -0.41 | -0.68 | - |
Diluted Shares Outstanding | 35.69M | 40.77M | 42.44M | 42.5M | 44.82M | 45.55M | 57.01M | 90.57M | 100.28M | 100.53M |
Basic Shares Outstanding | 35.69M | 40.77M | 42.44M | 42.5M | 44.82M | 45.55M | 57.01M | 90.57M | 100.28M | 100.53M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
CLLS Balance Sheet
Cellectis S.A. (CLLS) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 323.22M | 487.64M | 391.52M | 315.36M | 225.43M | 143.81M | 233.01M | 287.07M | 236.24M | 204.55M |
Cash & Short-Term Investments | 296.98M | 451.89M | 360.91M | 268.24M | 186.13M | 97.7M | 203.81M | 260.31M | 208.66M | 185.66M |
Cash Only | 296.98M | 451.89M | 360.91M | 241.15M | 185.64M | 89.79M | 136.71M | 143.25M | 63.58M | 35M |
Short-Term Investments | 0 | 0 | 0 | 27.09M | 499K | 7.91M | 67.11M | 117.06M | 145.08M | 150.66M |
Accounts Receivable | 4.57M | 22.07M | 15.29M | 19.19M | 31.07M | 17.57M | 23.13M | 23.04M | 22.2M | 15.05M |
Days Sales Outstanding | 66.15 | 632.66 | 367.48 | 137.22 | 373.74 | 334.59 | 11.18K | 202.59 | 111.07 | 124.68 |
Inventory | 250K | 275K | 2.9M | 1.61M | 0 | 0 | 0 | 0 | 0 | 0 |
Days Inventory Outstanding | 34.83 | 36.65 | 92.82 | 300.46 | - | - | - | - | - | - |
Other Current Assets | 2.99M | 2.42M | 594K | 12.21M | 50K | 22.31M | 345K | 298K | 5.38M | 338K |
Total Non-Current Assets | 9.66M | 13.2M | 75.95M | 154.11M | 156.65M | 117.41M | 101.27M | 96.48M | 88.48M | 84.64M |
Property, Plant & Equipment | 7.23M | 10.04M | 69.32M | 145.52M | 148.27M | 107.9M | 92.74M | 75.86M | 62.45M | 57.93M |
Fixed Asset Turnover | 3.49x | 1.27x | 0.22x | 0.35x | 0.20x | 0.18x | 0.01x | 0.55x | 1.17x | 1.06x |
Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Intangible Assets | 1.43M | 1.27M | 1.11M | 1.58M | 1.85M | 718K | 672K | 1.11M | 535K | 221K |
Long-Term Investments | 1M | 1.89M | 5.52M | 7.01M | 6.52M | 8.79M | 7.85M | 7.52M | 5.09M | 12.72M |
Other Non-Current Assets | 102K | -1K | 5.52M | -1K | 3K | 0 | -1K | 11.6M | 20.02M | 22.26M |
Total Assets | 332.88M▲ 0% | 500.84M▲ 50.5% | 467.47M▼ 6.7% | 469.47M▲ 0.4% | 382.08M▼ 18.6% | 261.22M▼ 31.6% | 334.27M▲ 28.0% | 383.54M▲ 14.7% | 324.72M▼ 15.3% | 289.19M▲ 0% |
Asset Turnover | 0.08x | 0.03x | 0.03x | 0.11x | 0.08x | 0.07x | 0.00x | 0.11x | 0.22x | 0.21x |
Asset Growth % | 0.67% | 50.46% | -6.66% | 0.43% | -18.62% | -31.63% | 27.97% | 14.74% | -15.34% | -62.32% |
Total Current Liabilities | 43.53M | 46.87M | 62.6M | 52.02M | 49.35M | 62.99M | 155.14M | 166.27M | 145.75M | 134.5M |
Accounts Payable | 9.46M | 15.88M | 29.26M | 24.61M | 23.76M | 21.46M | 19.07M | 18.66M | 17.28M | 17.09M |
Days Payables Outstanding | 1.32K | 2.12K | 937.62 | 4.6K | 4.7K | 923.08 | 938.16 | 741.93 | 643.68 | 503.02 |
Short-Term Debt | 0 | 0 | 0 | 0 | 2.25M | 4.97M | 5.16M | 4.84M | 18.16M | 15.16M |
Deferred Revenue (Current) | 26.06M | 20.75M | 20.03M | 452K | 301K | 59K | 110.33M | 112.16M | 96.8M | 397.25M |
Other Current Liabilities | 2.02M | 2.86M | 4.95M | 7.21M | 2.16M | 16.16M | 2.72M | 13.37M | 13.51M | 2.67M |
Current Ratio | 7.42x | 10.40x | 6.25x | 6.06x | 4.57x | 2.28x | 1.50x | 1.73x | 1.62x | 1.52x |
Quick Ratio | 7.42x | 10.40x | 6.21x | 6.03x | 4.57x | 2.28x | 1.50x | 1.73x | 1.62x | 1.52x |
Cash Conversion Cycle | -1.22K | -1.45K | -477.32 | -4.17K | - | - | - | - | - | -378.35 |
Total Non-Current Liabilities | 3.44M | 3.7M | 49.4M | 108.61M | 96.25M | 72.28M | 94.43M | 95.25M | 103.07M | 94.77M |
Long-Term Debt | 0 | 0 | 0 | 24.22M | 18.77M | 13.57M | 28.44M | 43.99M | 74.01M | 67.5M |
Capital Lease Obligations | 13K | 1.02M | 46.54M | 75.76M | 71.53M | 49.36M | 42.95M | 34.24M | 27.72M | 115.19M |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 158K | 0 | 0 | 0 |
Other Non-Current Liabilities | 3.43M | 2.68M | 2.85M | 8.63M | 5.96M | 9.35M | 22.88M | 17.02M | 1.33M | 1.32M |
Total Liabilities | 46.98M | 50.57M | 112M | 160.63M | 145.6M | 135.28M | 249.57M | 252.51M | 248.82M | 229.27M |
Total Debt | 34K | 1.35M | 47.61M | 106.68M | 100.87M | 75.77M | 85.06M | 91.46M | 119.9M | 108.6M |
Net Debt | -296.95M | -450.54M | -313.3M | -134.47M | -84.77M | -14.02M | -51.65M | -51.79M | 56.32M | 73.6M |
Debt / Equity | 0.00x | 0.00x | 0.13x | 0.35x | 0.43x | 0.60x | 1.00x | 0.70x | 1.58x | 1.81x |
Debt / EBITDA | - | - | - | - | - | - | - | - | - | -4.13x |
Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | -2.80x |
Interest Coverage | -185.14x | -122.11x | -38.05x | -14.01x | -21.20x | -25.04x | -20.95x | -3.93x | -7.39x | -8.34x |
Total Equity | 285.9M▲ 0% | 450.27M▲ 57.5% | 355.47M▼ 21.1% | 308.85M▼ 13.1% | 236.47M▼ 23.4% | 125.94M▼ 46.7% | 84.69M▼ 32.8% | 131.03M▲ 54.7% | 75.9M▼ 42.1% | 59.92M▲ 0% |
Equity Growth % | 4.33% | 57.49% | -21.05% | -13.12% | -23.43% | -46.74% | -32.75% | 54.71% | -42.07% | -147.53% |
Book Value per Share | 8.01 | 11.04 | 8.38 | 7.27 | 5.28 | 2.76 | 1.49 | 1.45 | 0.76 | 0.60 |
Total Shareholders' Equity | 266.79M | 409.3M | 315.12M | 283.8M | 221.29M | 117.97M | 84.69M | 131.03M | 75.9M | 59.92M |
Common Stock | 2.37M | 2.77M | 2.77M | 2.79M | 2.94M | 2.96M | 4.37M | 5.89M | 5.9M | 5.92M |
Retained Earnings | -351.3M | -405.32M | -508.48M | -587.03M | -698.33M | -439.5M | -405.77M | -329.61M | -334.13M | -351.94M |
Treasury Stock | -297K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | 1.98M | -16.67M | -22.64M | -4.09M | -18.02M | -28.61M | -36.69M | -39.54M | -33.32M | -33.2M |
Minority Interest | 19.11M | 40.97M | 40.35M | 25.05M | 15.18M | 7.97M | 0 | 0 | 0 | 0 |
CLLS Cash Flow Statement
Cellectis S.A. (CLLS) cash flow — operating, investing & free cash flow history
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | -52.33M | -68.14M | -69.14M | -80.26M | -104.56M | -87.44M | -24.75M | 22.1M | -40.14M | -37.91M |
Operating CF Margin % | -207.75% | -535.21% | -455.18% | -157.2% | -344.57% | -456.13% | -3277.62% | 53.25% | -55.02% | - |
Operating CF Growth % | -68.32% | -30.21% | -1.47% | -16.08% | -30.28% | 16.37% | 71.7% | 189.32% | -281.59% | -22221.24% |
Net Income | -103.68M | -88.33M | -115.21M | -53.58M | -96.75M | -98.69M | -116.83M | -36.7M | -67.8M | -67.29M |
Depreciation & Amortization | 3.37M | 2.38M | 6.88M | 7.83M | 14.16M | 18.43M | 18.52M | 19.84M | 20.12M | 19.68M |
Stock-Based Compensation | 50.42M | 37.22M | 26.88M | 10.03M | 11.49M | 6.04M | 5.23M | 0 | 0 | 1.28M |
Deferred Taxes | 4.32M | 6.46M | 0 | 0 | 0 | 87K | 371K | 0 | 0 | 0 |
Other Non-Cash Items | 11.04M | -16.76M | 661K | -27.22M | -21.16M | -7.6M | 71.95M | -14.61M | 49.26M | 19.72M |
Working Capital Changes | -17.79M | -9.1M | 11.65M | -17.32M | -12.3M | -5.72M | -3.99M | 53.57M | -41.72M | -11.31M |
Change in Receivables | -549K | -3.7M | 4.68M | -3.23M | -12.44M | -8.99M | 2.25M | -6.72M | -4.44M | 2.24M |
Change in Inventory | -109K | -37K | -2.63M | 100K | 215K | 0 | 0 | 0 | 0 | 0 |
Change in Payables | -335K | 9.37M | 9.63M | 5.69M | 177K | 3.25M | -6.3M | 2.05M | -3.27M | -1.34M |
Cash from Investing | 1.78M | 35.62M | -35.87M | -54.34M | 7.28M | -2.76M | -15.51M | -102.63M | -29.58M | -39.77M |
Capital Expenditures | -2.66M | -4.89M | -12.91M | -44.08M | -18.54M | -2.43M | -1.07M | -3.84M | -3.54M | -2.24M |
CapEx % of Revenue | 10.54% | 38.38% | 85.01% | 86.33% | 61.11% | 12.68% | 142.12% | 9.24% | 4.86% | 3.29% |
Acquisitions | 7.16M | 1.26M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Investments | - | - | - | - | - | - | - | - | - | - |
Other Investing | 7.16M | 1.26M | 369K | -13.15M | 10.96M | -456K | -14.44M | 0 | 0 | -2.26M |
Cash from Financing | 41.27M | 236.49M | -3.86M | 27.32M | 47.52M | 1.15M | 82.86M | 89.8M | -16.2M | -17.39M |
Debt Issued (Net) | -41K | -127K | -3.39M | 19.43M | -10.64M | -6.6M | 24.56M | 18.17M | -5.4M | -10.97M |
Equity Issued (Net) | 41.31M | 228.85M | 0 | 9.21M | 44.64M | -569K | 67.94M | 82.68M | 44.14K | 74.25K |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | -469K | 0 | 0 | -569K | 0 | 0 | 0 | 0 |
Other Financing | 0 | 7.77M | -469K | -1.32M | 13.53M | 8.32M | -9.63M | -11.04M | -10.85M | -6.49M |
Net Change in Cash | 1.81M▲ 0% | 195.12M▲ 10668.3% | -110.98M▼ 156.9% | -99.37M▲ 10.5% | -55.51M▲ 44.1% | -92.42M▼ 66.5% | 43.49M▲ 147.1% | 6.54M▼ 85.0% | -79.67M▼ 1317.6% | -94.68M▲ 0% |
Free Cash Flow | -54.98M▲ 0% | -73.02M▼ 32.8% | -82.1M▼ 12.4% | -124.68M▼ 51.9% | -123.12M▲ 1.3% | -89.89M▲ 27.0% | -25.82M▲ 71.3% | 19.52M▲ 175.6% | -42.5M▼ 317.7% | -40.14M▲ 0% |
FCF Margin % | -218.29% | -573.58% | -540.49% | -244.21% | -405.71% | -468.86% | -3419.74% | 47.04% | -58.27% | -58.95% |
FCF Growth % | -23.77% | -32.81% | -12.43% | -51.87% | 1.26% | 26.99% | 71.28% | 175.62% | -317.7% | -259.54% |
FCF per Share | -1.54 | -1.79 | -1.93 | -2.93 | -2.75 | -1.97 | -0.45 | 0.22 | -0.42 | -0.40 |
FCF Conversion (FCF/Net Income) | 0.53x | 0.87x | 0.68x | 0.99x | 0.92x | 0.82x | 0.24x | -0.60x | 0.59x | 0.60x |
Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
CLLS Key Ratios
Cellectis S.A. (CLLS) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | -35.49% | -21.38% | -25.34% | -24.41% | -41.88% | -58.57% | -95.96% | -34.08% | -65.33% | -80.73% |
Return on Invested Capital (ROIC) | - | - | -442.28% | -29.31% | -47.6% | -51.02% | -100.68% | -79.56% | -23.46% | -25.61% |
Gross Margin | 89.6% | 78.49% | 25% | 96.18% | 93.92% | 55.75% | -882.65% | 77.88% | 86.57% | 81.89% |
Net Margin | -394.51% | -618.12% | -672.09% | -158.79% | -376.32% | -553.64% | -13385.3% | -88.57% | -92.66% | -98.83% |
Debt / Equity | 0.00x | 0.00x | 0.13x | 0.35x | 0.43x | 0.60x | 1.00x | 0.70x | 1.58x | 1.81x |
Interest Coverage | -185.14x | -122.11x | -38.05x | -14.01x | -21.20x | -25.04x | -20.95x | -3.93x | -7.39x | -8.34x |
FCF Conversion | 0.53x | 0.87x | 0.68x | 0.99x | 0.92x | 0.82x | 0.24x | -0.60x | 0.59x | 0.60x |
Revenue Growth | -40.85% | -49.46% | 19.32% | 236.12% | -40.56% | -36.83% | -96.06% | 5397.48% | 75.76% | 42.95% |
Related:CLLS Dividend History·CLLS Revenue History·CLLS Price History·CLLS P/E History·CLLS Financial Ratios·CLLS Institutional Holders
CLLS Frequently Asked Questions
Cellectis S.A. (CLLS) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Cellectis S.A. (CLLS) reported $68.1M in revenue for fiscal year 2025. This represents a 1560% increase from $4.1M in 2007.
Cellectis S.A. (CLLS) grew revenue by 75.8% over the past year. This is strong growth.
Cellectis S.A. (CLLS) reported a net loss of $67.3M for fiscal year 2025.
Dividend & Returns
Cellectis S.A. (CLLS) has a return on equity (ROE) of -65.3%. Negative ROE indicates the company is unprofitable.
Cellectis S.A. (CLLS) had negative free cash flow of $40.1M in fiscal year 2025, likely due to heavy capital investments.